Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval

Stock Track11-28

Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.

The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.

Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116260561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116260561","market":"sg","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval","media":"Stock Track","content":"<p>Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.</p><p>The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.</p><p>Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-28 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.</p><p>The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.</p><p>Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1116260561","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116260561","pubTimestamp":1764341065,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股赛道|燃石生物盘中大涨5.44%因跌幅收窄及日本获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116260561","isCrawlerRequest":true}